Prograf and Glaucoma - a phase IV clinical study of FDA data

Summary:

Glaucoma is reported as a side effect among people who take Prograf (tacrolimus), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Prednisolone, and have Acute lymphocytic leukemia (all).

The phase IV clinical study analyzes which people have Glaucoma when taking Prograf. It is created by eHealthMe based on reports of 41,725 people who have side effects when taking Prograf from the FDA, and is updated regularly.

What is Prograf?

Prograf has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 42,230 Prograf users. Check the latest studies of Prograf.

What is Glaucoma?

Glaucoma (increased fluid pressure in the eye with vision loss) is found to be associated with 1,233 drugs and 1,657 conditions by eHealthMe. Check the latest studies of Glaucoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

41,725 people reported to have side effects when taking Prograf.
Among them, 47 people (0.11%) have Glaucoma.

Among these 47 people:

How long have people been on Prograf when they have Glaucoma? *

What is the gender of people who have Glaucoma when taking Prograf? *

female: 52.5 %
male: 47.5 %

What is the age of people who have Glaucoma when taking Prograf? *

What are other drugs people take besides Prograf? *

What are other side effects people have besides Glaucoma? *

Thrombocytopenia (decrease of platelets in blood): 10 people, 21.28%
Dyspnea (difficult or laboured breathing): 7 people, 14.89%
Mucormycosis (a rare infection caused by organisms that belong to a group of fungi called mucoromycotina): 7 people, 14.89%
Lymphocyte Count Decreased: 6 people, 12.77%
Urinary Tract Infection: 6 people, 12.77%
Cytomegalovirus Infection: 6 people, 12.77%
Sepsis (a severe blood infection that can lead to organ failure and death): 5 people, 10.64%
Headache (pain in head): 5 people, 10.64%
Intraocular Pressure Increased: 5 people, 10.64%
Diarrhea: 5 people, 10.64%

What are the existing conditions these people have? *

Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 6 people, 12.77%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 8.51%
Diarrhea: 4 people, 8.51%
Pain: 4 people, 8.51%
Fungal Infection: 4 people, 8.51%
Herpes Zoster: 3 people, 6.38%
Lumbar Spinal Stenosis (a medical condition in which the spinal canal narrows and compresses the spinal cord and nerves at the level of the lumbar bone): 3 people, 6.38%
Cytomegalovirus Infection: 3 people, 6.38%
Erection Problems: 3 people, 6.38%
Infection: 3 people, 6.38%

* Approximation only. Some reports may have incomplete information.

Do you take Prograf and have Glaucoma?

- Check whether Glaucoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Prograf:

Prograf (42,230 reports)

Glaucoma treatments and more:

Glaucoma (61,928 reports)

Browse all side effects of Prograf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Glaucoma:

Glaucoma (1,233 drugs)

Browse all the conditions that are associated with Glaucoma:

Glaucoma (1,657 conditions)

Related publications that referenced our studies

Hu CY, Lee BJ, Cheng HF, Wang CY, "Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient", Journal of glaucoma, 2015 Apr .
Hu CY, Lee BJ, Cheng HF, Wang CY, "Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient", Journal of glaucoma, 2015 Apr .

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus (the active ingredients of Prograf) and Prograf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.